Clinical trials: Nut Hypersensitivities
Tree Nut Allergy
Walnut Oral Immunotherapy for Tree Nut Allergy
The purpose of this study is to determine if walnut oral immunotherapy can be used in participants allergic to tree nuts to reduce tree nut allergy and induce changes in the participant's immune system.
- Trial name
- WOIT (NCT01546753)
- Testing
- Walnut Protein Powder, Open-label Walnut Protein Powder
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Arkansas
Peanut Allergy
A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal (ID) injection in adolescent participants with peanut allergy.
- Trial name
- NCT03755713
- Testing
- ASP0892
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Peanut Allergy
Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children
This is an open-label, follow-up study for subjects who completed the PEPITES study. Subjects will be offered enrollment in this follow-up study to receive Viaskin Peanut 250 μg for 2 additional years if previously on active…
- Trial name
- PEOPLE (NCT03013517)
- Testing
- Viaskin Peanut 250µg
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 300 people
- Sponsor
- DBV Technologies
Eczema, Egg Allergy
Promoting Tolerance to Peanut in High-Risk Children
This study will evaluate whether early exposure to peanuts promotes tolerance and provides protection from developing peanut allergy in children who are allergic to eggs or who have severe eczema.
- Conditions
- Eczema, Egg Allergy, Food Allergy
- Trial name
- LEAP (NCT00329784)
- Testing
- Peanut Consumption Group
- Where
- United Kingdom
- Volunteers
- 640 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Peanut Allergy
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing…
- Trial name
- NCT03682770
- Testing
- Dupilumab, AR101
- Where
- 25 sites in United States
- Volunteers
- 148 people
- Sponsor
- Regeneron Pharmaceuticals
Oral Immunotherapy for Food Allergy, Tree Nut Allergy
The NACHO Trial (Nut Allergy Children OIT)
Most food allergies that begin in early childhood are mild and resolve by school age, but nut allergies persist in about 80-90% of individuals into adulthood.
- Conditions
- Oral Immunotherapy for Food Allergy, Tree Nut Allergy, Cashew Nut Allergy
- Trial name
- NCT06930950
- Testing
- Cashew nut oral immunotherapy
- Where
- Finland
- Volunteers
- 45 people
- Sponsor
- HUS Skin and Allergy Hospital
Peanut Allergy
Evaluation of Allergenicity of Hypoallergenic Peanut Product in Peanut Allergic Subjects
This is a proof of concept study to determine the safety and allergenicity of hypoallergenic peanut product extract as compared to standard peanut extract in an adult population with known peanut allergy.
- Trial name
- peanut (NCT01489514)
- Testing
- Epicutaneous skin prick testing
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Allergy to Egg, Allergy to Peanut
Basophil Activation Test (BAT) Sensitivity in Child Food Allergy
Child food allergy represent 6 to 8% of child in industrialised country. Within this allergy, peanuts and egg allergy are one of the most common.
- Trial name
- TAB-TPO (NCT01966640)
- Testing
- Basophil Activation Test
- Where
- France
- Volunteers
- 140 people
- Sponsor
- University Hospital, Rouen
Allergy, Nut, Pediatric ALL
Efficiency And Tolerance Of Hazelnut Oral Immunotherapy Protocol In Hazelnut Allergic Children
Prevalence of food allergy in the world has been inscreasing in recent years. Among nut allergy, hazelnut allergy is the most widespread in Europe and particularly in France.
- Trial name
- ENOIME (NCT04841850)
- Testing
- Clinical and biological characteristics
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Hospices Civils de Lyon
Food Allergy in Infants, Nut Allergy
The TreEat Study- Can Early Introduction of Tree Nuts Prevent Tree Nut Allergy in Infants With Peanut Allergy
Early and regular ingestion of the common allergens, peanut and egg has been shown to be an effective allergy prevention strategy. It is not clear whether this is also true of tree nut allergy.
- Trial name
- TreEat (NCT04801823)
- Testing
- Home introduction, Multi Nut oral food challenge
- Where
- Australia
- Volunteers
- 212 people
- Sponsor
- Murdoch Childrens Research Institute
Food Hypersensitivity, Hypersensitivity
Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
The purpose of this study is to evaluate the safety and side effects of a study product that contains recombinant modified peanut proteins (EMP-123) in healthy and peanut-allergic participants. This is a first in human study.
- Conditions
- Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
- Trial name
- NCT00850668
- Testing
- E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Allertein Therapeutics, LLC
Peanut Allergy
The Grown Up Peanut Immunotherapy Study
To determine efficacy and safety of peanut oral immunotherapy in adults with peanut allergy.
- Trial name
- GUPI (NCT03648320)
- Testing
- Peanut oral immunotherapy
- Where
- United Kingdom
- Volunteers
- 33 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Peanut Allergy
Efficacy of Tezepelumab in Peanut Oral Immunotherapy
The proposed study is a proof-of-concept Phase 2, double-blind, randomized placebo-controlled clinical trial evaluating the safety and efficacy of tezepelumab and peanut Oral Immunotherapy (OIT) for the treatment of peanut…
- Trial name
- ZENITH (NCT07015996)
- Testing
- Tezepelumab, Peanut Oral Immunotherapy (OIT)
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Peanut Allergy
Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
The primary objective of the study is to assess the tolerability of peanut protein in pediatric patients (6-17 years old) treated with dupilumab monotherapy, in which tolerability is defined as the proportion of patients who…
- Trial name
- NCT03793608
- Testing
- Dupilumab
- Where
- 9 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Food Hypersensitivity, Peanut Hypersensitivity
An Observational Study of Childhood Food Allergy
The purpose of this study is to observe the natural course of food allergy, including both the development of peanut allergy in infants at high risk for developing this allergy, and the resolution of both egg and cow's milk…
- Conditions
- Food Hypersensitivity, Peanut Hypersensitivity, Egg Hypersensitivity, Milk Hypersensitivity
- Trial name
- NCT00356174
- Where
- 5 sites in United States
- Volunteers
- 515 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allergy, Peanut
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind…
- Trial name
- VITESSE (NCT05741476)
- Testing
- DBV712
- Where
- 87 sites in United States, Australia and 7 more
- Volunteers
- 600 people
- Sponsor
- DBV Technologies
Peanut Allergy
Validation of the HYPONUT Product
The HYPONUT product was previously validated in a laboratory setting ("Procédé de préparation d'aliment hypoallergénique", n° FR1250977) on 2012. A international patent was then obtained on 2013.
- Trial name
- NCT03849079
- Testing
- Hyponut
- Where
- France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Montpellier
Allergy, Asthma
Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders
This study will evaluate and follow patients with various allergic, hypersensitivity and inflammatory disorders. The protocol is not designed to test new treatments; patients will be managed with standard of care therapies.
- Conditions
- Allergy, Asthma, Allergic Rhinitis, Mastocytosis
- Trial name
- NCT00557895
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Peanut Allergy
PALISADE Follow-on Study (ARC004)
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
- Trial name
- NCT02993107
- Testing
- AR101
- Where
- 65 sites in United States, Canada and 7 more
- Volunteers
- 388 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)
- Trial name
- NCT07117669
- Testing
- ENP-501
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- N-Fold, LLC